Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed new GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Work at Janssen Pharmaceutica NV has led to the identification of lactam-containing imidazopyridazine interleukin-17A (IL-17A)/interleukin-17 receptor A (IL-17RA) interaction inhibitors.
The University of Virginia and Virginia Tech Intellectual Properties Inc. have patented protein spinster homolog 2 (SPNS2) inhibitors reported to be useful for the treatment of asthma, multiple sclerosis, chronic kidney disease and metastatic cancer.
Caraway Therapeutics Inc. patents describe new mucolipin (MCOLN; TRPML) activators reported to be useful for the treatment of aging, cancer, ciliopathies, glycogen and lysosomal storage diseases, macular degeneration, neurodegeneration and autosomal dominant polycystic kidney.
Glutamate oxaloacetate transaminase (GOT) is a glutamate scavenger that has been proposed to be used to counteract the excitotoxicity secondary to stroke or traumatic brain injury, among other pathologies. Furthermore, recent research suggests that mitochondrial GOT protects against energy failure after ischemia.
Spastic paraplegia type 47 (SPG47) is a rare congenital and neurological disorder characterized by dysfunction of the long axons in the corticospinal tract neurons that lead to progressive limb weakness and spasticity.
Cardiovascular disease is among the leading causes of death in individuals with type 2 diabetes. The role that microRNA 210 (miR-210) plays in endothelial cells and in diabetes-driven endothelial dysfunction is not clearly understood. Its potential as a therapeutic target was investigated.
The anti-HER2 biparatopic antibody (bpAb) KJ-015 was rationally designed at Shanghai Bao Pharmaceuticals Co. Ltd. by leveraging published antibody-antigen structures to share common light chain with two Fab arms, resulting in functionally balanced high affinity for two HER2 nonoverlapping epitopes.
Seaport Therapeutics Inc. has closed an oversubscribed $225 million series B financing round to support its work developing novel neuropsychiatric medicines.
RSS
